Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely?-Reference-Cited by-同舟云学术

Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely?

Published:2015-09-28 Issue:12 Volume:15 Page:1671-1675
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Doggrell Sheila Anne,Lynch Kaileen Anne

Publisher

Informa Healthcare

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1517/14712598.2015.1093109

Reference14 articles.

1. Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease

2. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

3. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

4. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

5. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 Targeting in the Management of Hypercholesterolaemia;EMJ Cardiology;2023-10-05

2. A heterogeneous network embedding framework for predicting similarity-based drug-target interactions;Briefings in Bioinformatics;2021-08-09

3. PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD);Advanced Pharmaceutical Bulletin;2020-08-09

4. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Efficacy and Safety in the Treatment of Hypercholesterolaemia;EMJ Diabetes;2018-11-20

5. Comentário a «Evolocumab e eventos clínicos em doentes com doenças cardiovasculares (estudo FOURIER)»;Revista Portuguesa de Cardiologia;2017-06